Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
The VRC07-523LS plus CAB-LA regimen maintained viral suppression in 93% of participants, with only transient infusion reactions observed; however, instances of virologic breakthrough suggest that future studies should focus on optimizing efficacy outcomes. These results support continued investigation of bNAb-based long-acting ART combinations.
Authors
- Jacqueline D. Reeves
- Susan L. Koletar (ORCID: https://orcid.org/0000-0003-1370-7438)
- Kimberly K. Scarsi (ORCID: https://orcid.org/0000-0001-9406-693X)
- Carl J. Fichtenbaum (ORCID: https://orcid.org/0000-0002-6778-7253)
- Edgar T. Overton (ORCID: https://orcid.org/0000-0002-4013-536X)
- Babafemi Taiwo (ORCID: https://orcid.org/0000-0003-2661-9103)
- Jorge Fuentes
- Charles Flexner (ORCID: https://orcid.org/0000-0002-4495-5349)
- Elizabeth R. Duke (ORCID: https://orcid.org/0000-0002-3348-9039)
- Virginia K. Sutton
- Jorge L. Santana Bagur
- Shaun Barcavage
- Teresa Spitz
- C Della Costanza
- Stephen Wolfe
- Leah Burke (ORCID: https://orcid.org/0000-0001-8220-3263)
- Christos J. Petropoulos (ORCID: https://orcid.org/0000-0001-5496-8090)
- Todd Stroberg
- Sigrid Pérez-Frontera
- William R. Short (ORCID: https://orcid.org/0000-0003-4225-8336)
- Anyelina Cantos (ORCID: https://orcid.org/0000-0002-2828-0281)
- David A. Wohl (ORCID: https://orcid.org/0000-0002-7764-0212)
- Sonal S. Munsiff (ORCID: https://orcid.org/0000-0002-7493-9163)
- Pablo Tebas (ORCID: https://orcid.org/0000-0001-5345-7942)
- Paul Wannamaker
- Ellen Lyda Burnham (ORCID: https://orcid.org/0000-0002-9945-0284)
- Lúcio Gama (ORCID: https://orcid.org/0000-0001-9511-012X)
- Amesika N. Nyaku (ORCID: https://orcid.org/0000-0002-1703-0500)
- Stephanie Solso
- Erin Hoffman
- Katharine J. Bar (ORCID: https://orcid.org/0000-0002-9773-0071)
- Sarah Trentman
- Constance A. Benson (ORCID: https://orcid.org/0000-0002-3781-1347)
- Rebecca C. Fry (ORCID: https://orcid.org/0000-0003-0899-9018)
- Pablo F. Belaunzarán-Zamudio (ORCID: https://orcid.org/0000-0003-4775-4734)
- Katherine Rodríguez (ORCID: https://orcid.org/0000-0001-9625-8839)
- Magdalena E. Sobieszczyk (ORCID: https://orcid.org/0000-0002-7112-3118)
- Chad J. Achenbach (ORCID: https://orcid.org/0000-0003-4847-7249)
- Suzanne Hendler
- Heather Harber
- Su Kyung Kim (ORCID: https://orcid.org/0000-0002-3710-153X)
- Yu Zheng (ORCID: https://orcid.org/0000-0002-3542-6410)
- Ronald D’Amico (ORCID: https://orcid.org/0000-0003-0828-0222)
- R Becker
- Michael Messer
- P. N. Rathod
- Azquena Munoz Lopez
- Susan E. Hulse
- Raghd Alyatim
- Joslyn Axinn
Institutions
- Northwestern University (US)
- National Institutes of Health (US)
- Harvard University (US)
- LabCorp (United States) (US)
- Cancer Research And Biostatistics (US)
- Yale New Haven Health System (US)
- National Institute of Allergy and Infectious Diseases (US)
- National Institutes of Health Clinical Center (US)
- Signal Systems Corporation (United States) (US)
- University of Nebraska Medical Center (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Clinical Infectious Diseases
- Published
- 2025-07-14
- DOI
- https://doi.org/10.1093/cid/ciaf375
- Citations
- 2
- Primary Topic
- HIV Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.07
Funders
- Vaccine Research Center
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases